Caitlin A. Brennan

TL;DR: This work has shown that natural killer cell killing of various tumors is inhibited in the presence of various F. nucleatum strains, and identified a bacterium-dependent, tumor-immune evasion mechanism in which tumors exploit the Fap2 protein of F. nucleus to inhibit immune cell activity via TIGIT.

TL;DR: This Review delves into recent insights and future directions for fusobacterial research, including the current genetic toolkit, the evolving understanding of its mechanistic role in promoting colorectal cancer and the challenges of developing diagnostics and therapeutics for F. nucleatum.

TL;DR: A host polysaccharide and fusobacterial lectin that explicates fusObacteria abundance in CRC is identified and targeting F. nucleatum Fap2 or host epithelial Gal-GalNAc may reduce fusOBacteria potentiation of CRC.

TL;DR: This work discusses both human data from meta'omics analyses and data from mechanistic studies in cell culture and animal models that support specific bacterial agents as potentiators of tumorigenesis and considers how microbes can be used in diagnosing colorectal cancer and manipulating the tumor environment to encourage better patient outcomes in response to immunotherapy treatments.

TL;DR: It is demonstrated that gut microbiota provide a net anabolic stimulus to the skeleton, which is likely mediated by IGF-1, and Supplementation of antibiotic-treated mice with short-chain fatty acids (SCFAs), products of microbial metabolism, restores IGF- 1 and bone mass to levels seen in nonantibiotic- treated mice.